Your browser doesn't support javascript.
loading
A Novel Diagnostic and Therapeutic Strategy for Cancer Patients by Integrating Chinese Medicine Syndrome Differentiation and Precision Medicine.
Yu, Shu-Xian; Liang, Zi-Mao; Wu, Qi-Biao; Shou, Lan; Huang, Xing-Xing; Zhu, Qian-Ru; Xie, Han; Mei, Ru-Yi; Zhang, Ruo-Nan; Zhai, Xiang-Yang; Xie, Tian; Sui, Xin-Bing.
Afiliação
  • Yu SX; School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China.
  • Liang ZM; Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
  • Wu QB; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
  • Shou L; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China.
  • Huang XX; School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China.
  • Zhu QR; Key Laboratory of Elemene Class Anti-cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
  • Xie H; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Hangzhou Normal University, Hangzhou, 311121, China.
  • Mei RY; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, China.
  • Zhang RN; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
  • Zhai XY; School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China.
  • Xie T; State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, China.
  • Sui XB; School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China.
Chin J Integr Med ; 28(10): 867-871, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35508859
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Chin J Integr Med Assunto da revista: TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Neoplasias / Antineoplásicos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Chin J Integr Med Assunto da revista: TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China